A Phase 2 interventional study of GSK3228836 and Placebo in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 121 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 7th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 23rd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 8 · Phase 4 10
First in 2000; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 457 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 163 across the 28 interventional studies, 172 across the 2 observational. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Hepatitis B, Chronic by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide therapy. This study is intended to evaluate if treatment with GSK3228836 can achieve sustained virologic response (SVR), that is hepatitis B virus surface antigen (HBsAg) less than (\<) lower limit of quantitation (LLOQ) and HBV deoxyribonucleic acid (DNA) \<LLOQ sustained for 24 weeks post-GSK3228836 treatment end. In addition, the study will also evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GSK3228836 in the 4 dosing regimens. This study will assess the efficacy and safety of treatment with GSK3228836 in two populations of participants with CHB; participants on stable nucleos(t)ide treatment (Cohort 1) and participants who are not currently on nucleos(t)ide therapy (Cohort 2). For each population, participants will be randomized into one of the 4 different parallel arms to receive treatment. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately, 440 participants will be enrolled in the study.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 457 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.
Drug: GSK3228836 · Drug: Nucleos(t)ide therapy
Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy
Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy
Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy
Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.
Drug: GSK3228836
Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.
Drug: GSK3228836 · Drug: Placebo
Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.
Drug: GSK3228836 · Drug: Placebo
Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.
Drug: GSK3228836 · Drug: Placebo
GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
Number of Participants Achieving Sustained Virologic Response (SVR)
The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication.
Time frame: Up to Week 48
Number of Participants Achieving HBsAg and HBV DNA<LLOQ
Participants achieving HBsAg and HBV DNA levels \<LLOQ at the end of treatment (EOT) were reported.
Time frame: Up to Week 26
Number of Participants With Categorical Changes From Baseline in HBsAg Values
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL).
Time frame: At Baseline and Week 24
Number of Participants With Categorical Changes From Baseline in HBV DNA Values
Participants who achieved a decline in HBV DNA values from baseline were reported. Participants were categorized in the following categorical HBV DNA decline of \<1, \>=1, \>=2, and \>=3 log IU/mL.
Time frame: At Baseline and Week 24
Number of Participants With Alanine Aminotransferase (ALT) Normalization
The ALT normalization (ALT≤ upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN. Participants who achieved ALT normalization were reported.
Time frame: At Baseline and Week 24
Median Time to ALT Normalization
Time to ALT normalization (ALT≤ULN) in the absence of rescue medication in participants with baseline ALT\>ULN. Numbers of participants analyzed at Week 24 include participants with baseline ALT \>ULN, and are as follows for NA therapy population: n=6 in GSK3228836 for 24 WK, n= 7 in GSK3228836 for 12 WK+12 WK, n=6 in GSK3228836 for 12 WK + Placebo for 12 WK, n=2 in Placebo for 12 WK + GSK3228836 for 12 WK, respectively. The numbers of participants analyzed are as follows for the not on NA therapy population: n=20 GSK3228836 for 24 WK, n=20 in GSK3228836 for 12 WK+12 WK, n=21 in GSK3228836 for 12 WK + Placebo for 12 WK, n=9 in Placebo for 12 WK + GSK3228836 for 12 WK arm, respectively.
Time frame: Baseline and up to Week 48
Number of Participants With Positive Hepatitis B Virus E-antibody (HBeAb)
Blood samples were collected to assess HBeAb level and participants with positive HBeAb were reported.
Time frame: Up to Week 48
Mean HBsAg and HBV DNA Level
Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points.
Time frame: At Baseline, Week 12, and 24
Mean Values of Hepatitis B Virus e Antigen (HBeAg) Level
Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).
Time frame: At Baseline, Week 12, and 24
Mean Change From Baseline in HBsAg and HBV DNA Level
Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 IU/mL = -0.03 log10 IU/mL).
Time frame: At Baseline, Week 12, and 24
Mean Change From Baseline in HBeAg Level
Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).
Time frame: At Baseline, Week 12, and 24
Mean Hepatitis B Virus Surface Antigen Antibody (Anti-HBsAg) Level
Blood samples were collected to assess anti-HBsAg level at indicated timepoints.
Time frame: At Baseline, Week 36, and 48
Mean Change From Baseline in Anti-HBsAg Level
Blood samples were collected to assess anti-HBsAg level at indicated timepoints.
Time frame: At Baseline, Week 12, and 24
Mean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK3228836
Intensive pharmacokinetic (PK) sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h of GSK3228836.
Time frame: Up to Week 24
Mean Maximum Observed Concentration (Cmax) of GSK3228836
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax of GSK3228836.
Time frame: Up to Week 24
Median Time of Maximum Observed Concentration (Tmax) of GSK3228836
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax of GSK3228836.
Time frame: Up to Week 24
Mean AUC0-24h of NA Therapies
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
Time frame: Up to Week 24
Mean Ctau of NA Therapies
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Ctau. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
Time frame: Up to Week 24
Mean Cmax of NA Therapies
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
Time frame: Up to Week 24
Median Tmax of NA Therapies
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
Time frame: Up to Week 24
Median Terminal Half-life (t1/2) of GSK3228836
Blood samples were collected from all participants for t1/2 analysis of GSK3228836. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.
Time frame: Up to Week 48
Mean Ctau of GSK3228836
Blood samples were collected from all participants for Ctau analysis of GSK3228836 at indicated. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.
Time frame: Up to Week 24
| Milestone | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Started | 68 | 68 | 68 | 23 | 70 | 68 | 68 | 24 |
| Completed | 65 | 65 | 66 | 22 | 64 | 66 | 63 | 24 |
| Not completed | 3 | 3 | 2 | 1 | 6 | 2 | 5 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 1 | 5 | 1 | 4 | 0 |
The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication.
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving Sustained Virologic Response (SVR) | 6 | 6 | 2 | 0 | 7 | 4 | 1 | 0 |
Participants achieving HBsAg and HBV DNA levels \<LLOQ at the end of treatment (EOT) were reported.
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving HBsAg and HBV DNA<LLOQ | 16 | 9 | 8 | 4 | 17 | 10 | 6 | 1 |
Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL).
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBsAg< LLOQ, at baseline | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HBsAg decline <0.5 log10 IU/mL | 12 | 21 | 37 | 4 | 8 | 14 | 29 | 8 |
| HBsAg decline >=0.5 log10 IU/mL | 52 | 42 | 20 | 17 | 55 | 48 | 22 | 15 |
| HBsAg decline >=1 log10 IU/mL | 48 | 38 | 14 | 17 | 51 | 36 | 18 | 15 |
| HBsAg decline >=1.5 log10 IU/mL | 42 | 32 | 12 | 15 | 48 | 30 | 9 | 12 |
| HBsAg decline >=3 log10 IU/mL | 34 | 16 | 5 | 10 | 35 | 13 | 4 | 9 |
Participants who achieved a decline in HBV DNA values from baseline were reported. Participants were categorized in the following categorical HBV DNA decline of \<1, \>=1, \>=2, and \>=3 log IU/mL.
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBV DNA < LLOQ, at Baseline | 66 | 66 | 66 | 22 | 0 | 0 | 0 | 0 |
| HBV DNA decline <1 log10 IU/mL | 2 | 0 | 0 | 0 | 3 | 12 | 21 | 3 |
| HBV DNA decline >=1 log10 IU/mL | 11 | 4 | 13 | 3 | 51 | 44 | 30 | 18 |
| HBV DNA decline >=2 log10 IU/mL | 0 | 0 | 0 | 0 | 40 | 23 | 19 | 14 |
| HBV DNA decline >=3 log10 IU/mL | 0 | 0 | 0 | 0 | 27 | 19 | 11 | 9 |
The ALT normalization (ALT≤ upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN. Participants who achieved ALT normalization were reported.
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Participants with ALT > ULN, at Baseline | 6 | 7 | 6 | 2 | 20 | 20 | 21 | 9 |
| Participants with ALT normalization, at Week 24 | 3 | 6 | 5 | 0 | 10 | 11 | 8 | 5 |
Time to ALT normalization (ALT≤ULN) in the absence of rescue medication in participants with baseline ALT\>ULN. Numbers of participants analyzed at Week 24 include participants with baseline ALT \>ULN, and are as follows for NA therapy population: n=6 in GSK3228836 for 24 WK, n= 7 in GSK3228836 for 12 WK+12 WK, n=6 in GSK3228836 for 12 WK + Placebo for 12 WK, n=2 in Placebo for 12 WK + GSK3228836 for 12 WK, respectively. The numbers of participants analyzed are as follows for the not on NA therapy population: n=20 GSK3228836 for 24 WK, n=20 in GSK3228836 for 12 WK+12 WK, n=21 in GSK3228836 for 12 WK + Placebo for 12 WK, n=9 in Placebo for 12 WK + GSK3228836 for 12 WK arm, respectively.
| Weeks | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Median Time to ALT Normalization | 16.6 (1.1 to NA) | 4.1 (1.0 to 11.9) | 1 (1.0 to 8.1) | 7 (1.1 to NA) | 13.4 (2.1 to NA) | 15.1 (4.3 to 18.1) | 10.7 (5.1 to 21.1) | 18.1 (1 to 32.1) |
Blood samples were collected to assess HBeAb level and participants with positive HBeAb were reported.
| Participants | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Positive Hepatitis B Virus E-antibody (HBeAb) | 3 | 4 | 5 | 2 | 6 | 4 | 6 | 3 |
Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points.
| Log10 (IU/mL) | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBsAg, at Baseline | 3.29 ± 0.623 | 3.26 ± 0.608 | 3.33 ± 0.588 | 3.43 ± 0.435 | 3.72 ± 0.771 | 3.64 ± 0.721 | 3.66 ± 0.675 | 3.76 ± 0.789 |
| HBsAg, at Week 12 | 1.20 ± 1.878 | 1.04 ± 1.858 | 1.76 ± 1.706 | 3.36 ± 0.431 | 1.39 ± 1.965 | 1.27 ± 2.000 | 1.57 ± 1.808 | 3.68 ± 0.798 |
| HBsAg, at Week 24 | 0.65 ± 1.939 | 1.45 ± 1.809 | 2.51 ± 1.536 | 0.83 ± 1.801 | 0.77 ± 2.016 | 1.88 ± 1.915 | 2.88 ± 1.511 | 1.64 ± 2.171 |
| HBV DNA, at Baseline | 0.48 ± 0.638 | 0.39 ± 0.603 | 0.53 ± 0.659 | 0.40 ± 0.622 | 5.02 ± 1.527 | 5.14 ± 1.557 | 4.67 ± 1.497 | 5.57 ± 1.654 |
| HBV DNA, at Week 12 | 0.74 ± 0.654 | 0.86 ± 0.700 | 0.67 ± 0.785 | 0.61 ± 0.682 | 3.00 ± 2.242 | 2.92 ± 2.142 | 2.68 ± 1.996 | 4.96 ± 2.074 |
| HBV DNA, at Week 24 | 0.55 ± 0.654 | 0.56 ± 0.649 | 0.56 ± 0.714 | 0.79 ± 0.667 | 2.37 ± 2.137 | 2.93 ± 2.317 | 3.07 ± 1.938 | 3.04 ± 2.224 |
Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).
| Log10 unit per milliliter (U/mL) | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBeAg, at Baseline | 0.49 ± 1.014 | 0.12 ± 0.756 | 0.36 ± 1.053 | 0.63 ± 1.323 | 2.13 ± 1.564 | 2.52 ± 0.919 | 1.77 ± 1.612 | 2.84 ± 0.743 |
| HBeAg, at Week 12 | 0.06 ± 1.027 | -0.21 ± 0.732 | 0.19 ± 1.089 | 0.60 ± 1.310 | 1.84 ± 1.805 | 1.52 ± 1.831 | 1.07 ± 1.551 | 2.79 ± 0.725 |
| HBeAg, at Week 24 | -0.41 ± 0.635 | -0.48 ± 0.752 | -0.19 ± 1.071 | 0.08 ± 1.497 | 1.18 ± 2.064 | 1.34 ± 1.936 | 0.89 ± 1.667 | 1.06 ± 2.165 |
Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 IU/mL = -0.03 log10 IU/mL).
| log IU/mL | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBsAg, at Baseline | 3.29 ± 0.623 | 3.26 ± 0.608 | 3.33 ± 0.588 | 3.43 ± 0.435 | 3.72 ± 0.771 | 3.64 ± 0.721 | 3.66 ± 0.675 | 3.76 ± 0.789 |
| HBsAg, at Week 12 | -2.09 ± 1.649 | -2.23 ± 1.597 | -1.59 ± 1.474 | -0.03 ± 0.089 | -2.37 ± 1.585 | -2.41 ± 1.562 | -2.06 ± 1.638 | -0.08 ± 0.292 |
| HBsAg, at Week 24 | -2.62 ± 1.653 | -1.81 ± 1.488 | -0.83 ± 1.248 | -2.57 ± 1.671 | -2.96 ± 1.656 | -1.77 ± 1.489 | -0.77 ± 1.108 | -2.09 ± 1.764 |
| HBV DNA, at Baseline | 3.29 ± 0.623 | 3.26 ± 0.608 | 3.33 ± 0.588 | 3.43 ± 0.435 | 3.72 ± 0.771 | 3.64 ± 0.721 | 3.66 ± 0.675 | 3.76 ± 0.789 |
| HBV DNA, at Week 12 | 0.24 ± 0.793 | 0.47 ± 0.773 | 0.16 ± 0.942 | 0.19 ± 0.727 | -1.96 ± 1.365 | -2.22 ± 1.592 | -1.92 ± 1.349 | -0.54 ± 1.421 |
| HBV DNA, at Week 24 | 0.06 ± 0.831 | 0.17 ± 0.661 | 0.09 ± 0.928 | 0.33 ± 0.928 | -2.66 ± 1.646 | -2.2 ± 1.68 | -1.52 ± 1.637 | -2.6 ± 2.001 |
Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).
| Log u/mL | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| HBeAg, at Baseline | 0.49 ± 1.014 | 0.12 ± 0.756 | 0.36 ± 1.053 | 0.63 ± 1.323 | 2.13 ± 1.564 | 2.52 ± 0.919 | 1.77 ± 1.612 | 2.84 ± 0.743 |
| HBeAg, at Week 12 | -0.52 ± 0.874 | -0.42 ± 0.480 | -0.33 ± 0.343 | -0.17 ± 0.453 | -0.65 ± 0.919 | -1.25 ± 1.522 | -0.94 ± 1.618 | -0.14 ± 0.313 |
| HBeAg, at WeeK 24 | -0.85 ± 1.071 | -0.56 ± 0.811 | -0.46 ± 0.595 | -0.56 ± 0.598 | -1.01 ± 1.426 | -1.18 ± 1.532 | -0.70 ± 1.673 | -1.78 ± 2.057 |
Blood samples were collected to assess anti-HBsAg level at indicated timepoints.
| Log10 IU/mL | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| At baseline | 0.67 ± 0.289 | 0.65 ± 0.165 | 0.64 ± 0.129 | 0.66 ± 0.287 | 0.65 ± 0.284 | 0.69 ± 0.303 | 0.62 ± 0.150 | 0.74 ± 0.307 |
| At Week 36 | 0.94 ± 0.534 | 0.83 ± 0.401 | 0.74 ± 0.333 | 0.79 ± 0.368 | 1.01 ± 0.660 | 0.82 ± 0.385 | 0.74 ± 0.347 | 0.90 ± 0.437 |
| At Week 48 | 0.88 ± 0.471 | 0.77 ± 0.368 | 0.70 ± 0.277 | 0.75 ± 0.326 | 0.91 ± 0.567 | 0.79 ± 0.369 | 0.71 ± 0.296 | 0.83 ± 0.356 |
Blood samples were collected to assess anti-HBsAg level at indicated timepoints.
| Log10 IU/mL | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| At Baseline | 0.67 ± 0.289 | 0.65 ± 0.165 | 0.64 ± 0.129 | 0.66 ± 0.287 | 0.65 ± 0.284 | 0.69 ± 0.303 | 0.62 ± 0.150 | 0.74 ± 0.307 |
| At Week 12 | 0.28 ± 0.481 | 0.18 ± 0.343 | 0.11 ± 0.319 | 0.13 ± 0.250 | 0.37 ± 0.615 | 0.13 ± 0.353 | 0.12 ± 0.221 | 0.16 ± 0.355 |
| At Week 24 | 0.22 ± 0.429 | 0.12 ± 0.335 | 0.07 ± 0.267 | 0.09 ± 0.239 | 0.26 ± 0.507 | 0.10 ± 0.319 | 0.09 ± 0.203 | 0.09 ± 0.203 |
Intensive pharmacokinetic (PK) sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h of GSK3228836.
| hour*micrograms per milliliter (h*ug/mL) | GSK3228836 Dose Level 150mg | GSK3228836 Dose Level 300mg |
|---|---|---|
| Mean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK3228836 | 55.214 ± 22.9901 | 140.312 ± 37.3548 |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax of GSK3228836.
| ug/mL | GSK3228836 Dose Level 150mg | GSK3228836 Dose Level 300mg |
|---|---|---|
| Mean Maximum Observed Concentration (Cmax) of GSK3228836 | 6.112 ± 2.8112 | 14.956 ± 5.6592 |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax of GSK3228836.
| hour | GSK3228836 Dose Level 150mg | GSK3228836 Dose Level 300mg |
|---|---|---|
| Median Time of Maximum Observed Concentration (Tmax) of GSK3228836 | 3.008 (2.00 to 4.02) | 3.017 (2.00 to 5.00) |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
| h*nanograms per milliliter (h*ng/mL) | Tenofovir Disoproxil Fumarate | Tenofovir Alafenamide | Entecavir |
|---|---|---|---|
| Mean AUC0-24h of NA Therapies | 2753.908 ± 661.3392 | 308.167 ± 104.8297 | 24.43 ± 6.761 |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Ctau. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
| ng/mL | Tenofovir Disoproxil Fumarate | Tenofovir Alafenamide | Entecavir |
|---|---|---|---|
| Mean Ctau of NA Therapies | 57.04 ± 17.0787 | 10.31 ± 3.4802 | 0.478 ± 0.1055 |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
| ng/mL | Tenofovir Disoproxil Fumarate | Tenofovir Alafenamide | Entecavir |
|---|---|---|---|
| Mean Cmax of NA Therapies | 318.857 ± 95.94 | 19.36 ± 5.85 | 6.526 ± 2.27 |
Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.
| hour | Tenofovir Disoproxil Fumarate | Tenofovir Alafenamide | Entecavir |
|---|---|---|---|
| Median Tmax of NA Therapies | 1 (0.52 to 1.47) | 1.417 (0.93 to 1.55) | 0.983 (0.48 to 2.02) |
Blood samples were collected from all participants for t1/2 analysis of GSK3228836. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.
| Day | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) |
|---|---|---|---|---|
| Median Terminal Half-life (t1/2) of GSK3228836 | 28.897 (7.52 to 191.98) | 24.918 (8.84 to 216.43) | 27.846 (10.19 to 149.74) | 38.205 (6.87 to 161.83) |
Blood samples were collected from all participants for Ctau analysis of GSK3228836 at indicated. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.
| ng/mL | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) |
|---|---|---|---|---|
| At Week 8 | 21.009 ± 9.6214 | 47.039 ± 198.1345 | 21.663 ± 14.4479 | 23.46 ± 16.6498 |
| At Week 12 | 23.162 ± 11.8963 | 23.234 ± 11.6993 | 21.777 ± 9.9248 | 22.789 ± 11.7361 |
| At Week 24 | 31.102 ± 28.7535 | 18.95 ± 14.6513 | 28.158 ± 17.0606 | 20.138 ± 19.023 |
Collected over All adverse events (AEs) and serious adverse events (SAEs) were collected from the signing of the informed consent until the final follow-up visit, up to 48 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK3228836 for 24 Weeks (WK) (on NA Therapy) | 0/68 (0%) | 1/68 (1.5%) | 56/68 (82.4%) |
| GSK3228836 for 12+12 WK (on NA Therapy) | 0/67 (0%) | 1/67 (1.5%) | 59/67 (88.1%) |
| GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | 0/68 (0%) | 4/68 (5.9%) | 53/68 (77.9%) |
| Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | 0/23 (0%) | 0/23 (0%) | 16/23 (69.6%) |
| GSK3228836 for 24 WK (Not on NA Therapy) | 0/70 (0%) | 6/70 (8.6%) | 65/70 (92.9%) |
| GSK3228836 for 12+12 WK (Not on NA Therapy) | 0/67 (0%) | 2/67 (3%) | 60/67 (89.6%) |
| GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | 0/68 (0%) | 3/68 (4.4%) | 61/68 (89.7%) |
| Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) | 0/24 (0%) | 0/24 (0%) | 19/24 (79.2%) |
| Event | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 1/67 | 0/68 | 0/24 |
| Muscle injuryInjury, poisoning and procedural complications | 0/68 | 1/67 | 0/68 | 0/23 | 0/70 | 0/67 | 0/68 | 0/24 |
| Spinal column injuryInjury, poisoning and procedural complications | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 1/67 | 0/68 | 0/24 |
| HaemorrhoidsGastrointestinal disorders | 0/68 | 0/67 | 1/68 | 0/23 | 0/70 | 0/67 | 0/68 | 0/24 |
| ConcussionInjury, poisoning and procedural complications | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 0/67 | 1/68 | 0/24 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 0/67 | 1/68 | 0/24 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 0/67 | 1/68 | 0/24 |
| Cerebral infarctionNervous system disorders | 0/68 | 0/67 | 1/68 | 0/23 | 0/70 | 0/67 | 0/68 | 0/24 |
| Cervical dysplasiaReproductive system and breast disorders | 0/68 | 0/67 | 0/68 | 0/23 | 0/70 | 0/67 | 1/68 | 0/24 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/68 | 0/67 | 1/68 | 0/23 | 0/70 | 0/67 | 0/68 | 0/24 |
| Event | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) |
|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 36/68 | 37/67 | 34/68 | 5/23 | 34/70 | 30/67 | 37/68 | 10/24 |
| Injection site pruritusGeneral disorders | 14/68 | 17/67 | 15/68 | 2/23 | 23/70 | 16/67 | 19/68 | 2/24 |
| Injection site painGeneral disorders | 11/68 | 15/67 | 21/68 | 6/23 | 20/70 | 13/67 | 14/68 | 6/24 |
| PyrexiaGeneral disorders | 10/68 | 6/67 | 10/68 | 6/23 | 15/70 | 17/67 | 17/68 | 4/24 |
| Alanine aminotransferase increasedInvestigations | 7/68 | 8/67 | 4/68 | 5/23 | 17/70 | 15/67 | 12/68 | 4/24 |
| HeadacheNervous system disorders | 5/68 | 6/67 | 8/68 | 3/23 | 14/70 | 14/67 | 14/68 | 4/24 |
| Injection site bruisingGeneral disorders | 7/68 | 11/67 | 7/68 | 4/23 | 13/70 | 10/67 | 14/68 | 4/24 |
| Injection site discolourationGeneral disorders | 8/68 | 9/67 | 14/68 | 2/23 | 13/70 | 11/67 | 6/68 | 2/24 |
| Injection site swellingGeneral disorders | 4/68 | 4/67 | 13/68 | 1/23 | 10/70 | 7/67 | 5/68 | 0/24 |
| FatigueGeneral disorders | 5/68 | 4/67 | 7/68 | 1/23 | 13/70 | 7/67 | 8/68 | 0/24 |
| Age, Continuous(YEARS) | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 49.0 ± 11.54 | 46.1 ± 12.60 | 47.4 ± 11.18 | 49.8 ± 11.21 | 44.5 ± 11.10 | 43.8 ± 9.92 | 40.7 ± 11.10 | 42.4 ± 12.02 | 42.9 ± 10.90 |
| Sex: Female, Male(Participants) | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 20 | 19 | 17 | 6 | 37 | 27 | 29 | 13 | 168 |
| Male | 48 | 49 | 51 | 17 | 33 | 41 | 39 | 11 | 289 |
| Race/Ethnicity, Customized(Participants) | GSK3228836 for 24 Weeks (WK) (on NA Therapy) | GSK3228836 for 12+12 WK (on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy) | GSK3228836 for 24 WK (Not on NA Therapy) | GSK3228836 for 12+12 WK (Not on NA Therapy) | GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy) | Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy) | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 36 | 35 | 36 | 12 | 37 | 44 | 38 | 12 | 250 |
| Black or African American | 2 | 1 | 4 | 0 | 9 | 4 | 6 | 1 | 27 |
| Mixed Race | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 30 | 32 | 26 | 11 | 24 | 20 | 24 | 11 | 178 |
Showing the first 100 of 121 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Mar 2022, 19 months.
Results were first posted in May 2023, 1 year 1 month after primary completion.
Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 19 months is below that.
Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bepirovirsen